Sweet Preference and Alcohol Craving

Completed · Phase 2 · Has a placebo group

Conditions studied: Alcohol Dependence, Alcohol Abuse

In brief

Purpose: The proposed 2-year investigation will be the first double-blind, placebo-controlled trial examining the hedonic response to sweet taste (HRST) as a phenotypic predictor of naltrexone (NTX) response in alcohol dependence. HRST yields two primary phenotypes-Sweet Likers (SL) and Sweet Dislikers (SDL). Based on preliminary findings, HRST will be examined in conjunction with craving for alcohol to assess whether the two factors together provide a more robust predictor of NTX response. The identification of methods to predict naltrexone response in alcohol dependence is an important goal for alcohol treatment research. Currently naltrexone is not being used nearly as much as it should be, in part because clinicians do not believe it is very effective. The development of tools that would identify which patients are more likely to have a robust response to naltrexone should lead to increased use of the medication. This could help many patients who are not now having the opportunity of trying naltrexone. There are two principal Specific Aims for the study: Specific Aim 1. To test the hypothesis that a combination of SL/SDL status and initial alcohol craving will predict % abstinent days (%ABST) during treatment with naltrexone. Specific Aim 2. To test whether a combination of SL/SDL status and initial alcohol craving predict % heavy drinking days (%HDD) during treatment with naltrexone.

Key facts

Study ID

NCT01296646

Run by

University of North Carolina, Chapel Hill

People needed

80

Starts

2010-01-01

Expected to finish

2012-06-01

Last updated by the study team

2013-11-25

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men and women between the ages of 18 and 65 meeting DSM-IV criteria for current alcohol dependence.
• More than 14 drinks (women) or 21 drinks (men) per week including at least 2 heavy drinking days/week on average (men > 5 drinks/day; women > 4 drinks/day) during a consecutive 30-day period within the 90 days prior to screening.
• Ability to understand and sign written informed consent.
• Must have a 0.0 gms/dL breathalyzer reading on the day of screening and 0.0 gms/dL on the day of randomization.
• Must be willing to refrain from drinking for three days prior to randomization day.
• Express a desire to achieve abstinence or to greatly reduce alcohol consumption.
• Must have a stable residence and be able to identify an individual who could locate subject if needed.

You may not qualify if…

• Clinically significant medical disease that might interfere with the evaluation of the study medication or present a safety concern (e.g., cirrhosis, unstable hypertension, seizure disorder, use of opiate medication).
• Clinically significant psychiatric illness including: any psychotic disorder, bipolar disorder, severe depression, or suicidal ideation.
• Other substance abuse or dependence disorder other than nicotine or alcohol.
• Concurrent use of any psychotropic medication including antidepressants, mood stabilizers, antipsychotics, anxiolytics, stimulants, or hypnotics with the exception of stable doses of antidepressants for one month.
• History of complicated alcohol withdrawal, i.e. withdrawal seizure or delirium tremens.
• AST, or ALT > 3 times Upper Limit of Normal (ULN) or bilirubin > ULN.
• Positive urine toxicology screen with the exception of cannabis. Individuals with positive cannabis screens will be excluded only if they have a history of cannabis dependence.
• Pregnant women and women of childbearing potential who do not practice a medically acceptable form of birth control (oral or depot contraceptive, or barrier methods such as diaphragm or condom with spermicidal) and women who are breast feeding.
• Individuals requiring inpatient treatment or more intense outpatient treatment for their alcohol dependence.
• Participation in any clinical trial within the past 60 days.
• Court-mandated participation in alcohol treatment or pending incarceration.

Where it is running

• University of North Carolina - Chapel Hill — Chapel Hill, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.